Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04798989 · ClinicalTrials.gov registry record · Phase 2
A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology
A Phase 2 study, sponsored by Tisento Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04798989 is a Phase 2 study that was terminated before completion, run by Tisento Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT04798989, a Phase 2 study, was terminated before completion, sponsored by Tisento Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study is being conducted to test the safety, tolerability, and pharmacokinetics of the investigational drug CY6463 compared with placebo in individuals who are aged 60 years or older and have Alzheimer's disease (AD) along with common cardiovascular risk factors.
Interventions
- DRUG Placebo
- DRUG CY6463
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-11-02 |
| Est. Completion | 2022-11-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04798989
The ClinicalTrials.gov registry entry for NCT04798989 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tisento Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04798989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04798989 about?
NCT04798989 is a clinical study titled "A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology". This study is being conducted to test the safety, tolerability, and pharmacokinetics of the investigational drug CY6463 compared with placebo in individuals who are aged 60 years or older and have Alzheimer's disease (AD) along with common cardiovascular risk factors.
What is the current status of trial NCT04798989?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-11-02. Estimated completion is 2022-11-28.
What interventions are being tested in trial NCT04798989?
The interventions under investigation include: Placebo (DRUG), CY6463 (DRUG).
Who is sponsoring clinical trial NCT04798989?
This trial is sponsored by Tisento Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.